ExonHit licenses Merck rights to RNA splicing microarray patent

ExonHit Therapeutics S.A., a drug and diagnostic discovery company, has announced that Merck & Co., Inc. has been granted a non-exclusive license to rights for research only under Patent US 6,881,571.

It is not anticipated that the revenues received by ExonHit from Merck under this agreement will exceed US$150,000 per year.

Patent US 6,881,571, entitled "Qualitative Differential Screening", was granted on April 19, 2005 and has claims directed to microarrays optimized for the monitoring of RNA splicing events.